Compare Petróleo Brasileiro SA (PBR) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Petróleo Brasileiro SA vs Pfizer Inc — how do they compare? Petróleo Brasileiro SA trades at $18.92 (market cap $112.59B), while Pfizer Inc trades at $24.89 (market cap $142.14B). The key difference: Pfizer Inc is the larger of the two by market cap, and Petróleo Brasileiro SA pays the higher dividend (9.51%). Which is the better fit depends on your goals.
| PBR | PFE | |
|---|---|---|
Market Cap | $112.59B | $142.14B |
Sector | Technology | Health |
52-Week High | $22.03 | $28.56 |
52-Week Low | $11.54 | $23.29 |
Enterprise Value | $176.05B | $192.80B |
Dividend Yield | 9.51% | 6.9% |
Volume | — | 29,869,932 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PBR trades at $18.19, up 1.22% today, with a bullish technical signal from moving averages. The stock shows strong fundamentals with a low P/E of 5.73 and robust profitability, including a 21.47% net income margin. Recent news highlights expansion in deepwater operations and strategic partnerships, while earnings have mostly beaten expectations except for a Q1 2026 miss.
The outlook is positive, supported by attractive valuation, solid cash flows, and dividend payments. Risks include oil price volatility and execution of new projects. Analyst consensus leans bullish with 50% buy ratings, but overbought RSI levels suggest near-term caution.
Pfizer (PFE) trades at $24.75, down 1.2% on the day, with a neutral technical outlook. The company maintains strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $0.75 beating expectations of $0.722. Pfizer demonstrates robust profitability with a 73.51% gross margin and 11.83% net income margin, though revenue has moderated from pandemic peaks. Recent news highlights the company's focus on AI drug discovery and pipeline development.
Pfizer presents a value opportunity trading below analyst consensus target of $28.25, with 38% of analysts rating it Buy. The stock offers a solid dividend yield with recent $0.43 payments. Key risks include patent expirations and revenue normalization post-COVID, while catalysts include obesity and oncology pipeline developments in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Petróleo Brasileiro SA
Petróleo Brasileiro S.A., commonly known as Petrobras, is a state-controlled Brazilian multinational corporation in the oil and gas industry. The company is one of the world's largest producers of oil and gas, primarily operating in exploration, production, refining, and power generation. Petrobras is particularly known for its deep-sea and ultra-deep-sea exploration and production activities in the vast pre-salt offshore reserves, which are a major component of Brazil's economy.
Read more on PBR →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
